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The aim was to compare population-based survival for exocrine pancreatic cancer in England in the 




We examined incidence for adults diagnosed with a pancreatic exocrine cancer during 1995-2014 
and age-standardised net survival up to five years after diagnosis for patients diagnosed during 2000-
2013. We examined variation in regional resection rates and survival for patients diagnosed during 
2010-2013. The data were extracted from the National Cancer Registration and Analysis Service. 
 
Results 
Age-standardised annual incidence rates of exocrine pancreatic cancer increased from 17.1 per 105 
during 1995-1999 to 18.7 during 2010-2014. Age-standardised one-year and five-year net survival 
increased from 17.9% and 3.6%, respectively, for 2000-2009, to 21.6% and 4.2% during 2010-2013. 
There were 2,086 (8.9%) resections among 23,415 patients in 2010-2013. The proportion ranged 
from 5.1% to 19.6% between centres. Among resected patients, survival was 73.0% at one year and 
20.2% at five years. Of the 2,118 resected patients, 18 (0.9%) were at stage 1; 34 (1.6%) at stage 2; 
791 (37.3%) at stage 3 and 140 (6.6%) at stage 4, although 53.6% of stage information was missing.  
Five-year survival was 2.1% for those who were not resected. The number of resections performed 
in each centre was not correlated with one-year survival.  
 
Conclusions 
Despite improvements in the management of pancreatic cancer in England with the introduction of 
specialist centres, resection rates remain relatively low, and survival remains lower than in 
comparably wealthy countries.  
 




Pancreatic cancer is one of the most lethal cancers in adults. It is estimated that almost 460,000 cases 
occurred world-wide in 2018, with 430,000 deaths. (1) In England, survival is the lowest among the 
10 most common cancers. (2) Unfortunately, there is currently no viable screening test for pancreatic 
cancer, (3) but there has been some improvement in outcome in recent years, especially among the 
15-20% of patients who can have removal of the cancer by surgery, followed by adjuvant 
chemotherapy. (4-6) Trials have shown a small to modest improvement in the 30% of patients with 
locally advanced disease, and for patients with metastatic disease who have good performance 
status. (7, 8) 
Cancer incidence and mortality rates vary widely, (9) but five-year survival from cancer in Europe 
has improved over the past 20 years.(10) Disparities in cancer survival persist, even between high-
income countries. (11)  Stage of disease at diagnosis, timely access to effective treatment, and the 
extent of comorbidity are probably the main determinants of patient outcomes. (12)  
In the UK, wide disparities in surgical outcomes for pancreatic cancer between District General 
Hospitals and specialist tertiary centres led to the introduction of centralised pancreatic centres 
between 2001 and 2006. (13-15) Each centre covers a population of 2 to 4 million people, either as 
a stand-alone pancreas-specific centre or as part of a Hepato-Pancreato-Biliary (HPB) centre.  (16) 
Patients referred to a pancreatic centre are given a diagnosis, and the specialist Multidisciplinary 
Team (sMDT) decides the best management. Surgical resection is carried out in the specialist centre, 
but oncological medical therapy and palliative care are undertaken either centrally or at the referring 
unit.  
This is the first study to evaluate national incidence and survival trends for pancreatic cancer, and 
to assess variation in survival between areas covered by the 23 pancreatic cancer specialist centres 
for all patients in England, both for all patients and for those who had a resection.  
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DATA AND METHODS 
Study Design 
We calculated age-standardised annual incidence rates for all adults (15-99 years) diagnosed with a 
primary, invasive, malignant neoplasm of the pancreas in England between 1 January 1995 and 31 
December 2014. We also estimated age-standardised net survival up to five years after diagnosis. 
The cohort approach was used for patients diagnosed between 1 January 2000 and 31 December 
2009, all of whom were followed up for at least five years by 31 December 2014. The period 
approach was used to obtain short-term predictions of five-year survival for patients diagnosed 
between 1 January 2010 and 31 December 2013. (17)  
This study is part of the Cancer Survival Programme, approved by the Ethics Committee of the 
London School of Hygiene and Tropical Medicine (#11984, updated 6 April 2018).  
Data 
The main source of information was the National Cancer Registry database, which was maintained 
by the Office for National Statistics (ONS) at the time of data acquisition. Cancer records were 
linked to Hospital Episode Statistics (HES) records and the Cancer Analysis System (CAS) to derive 
data on treatment and stage. These databases are now maintained by the National Cancer 
Registration and Analysis Service (NCRAS) in Public Health England (PHE).  
Extensive quality control of the data was performed. Details of the eligibility and exclusion criteria 
have been described. (18) Patients for whom a death certificate or autopsy report was the only 
information available, were excluded from survival analysis because their duration of survival was 
unknown, but these patients were included in the calculation of incidence rates for the year of their 
death. Patients whose vital status was unknown, those aged 100 years or over at diagnosis and those 
whose records contained invalid dates or date sequences were also excluded from survival analysis.  
Tumour morphology was coded according to the World Health Organisation’s International 
Classification of Diseases for Oncology (revision 3.1).(19) Tumours were grouped into three broad 
morphologic categories for analysis: exocrine carcinomas, pancreatic neuroendocrine tumours 
(PNET), and other malignant cancers of the pancreas.  
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Pancreatic cancer specialist centres 
For survival analysis, patients were allocated to one of the 23 areas covered by each pancreatic 
centre, by mapping all National Health Service (NHS) Trust hospitals, hospices and Primary Care 
Units, using treatment information from Hospital Episode Statistics. Each region represents one of 
the 23 pancreatic centres and its local providers. Patients were allocated to the hospital where they 
received surgery, or if not, chemotherapy or radiotherapy. If no treatment had been recorded, they 
were allocated to the hospital where they were diagnosed. Specialists in each centre agreed the 
mapping of hospitals to pancreatic centres, with the exception of Cambridge, Blackburn, Hull and 
North West London. This was a population-based analysis for residents of England, so patients 
resident in other UK nations (Wales, Northern Ireland, Scotland), or Ireland, but who were treated 
in a pancreatic centre in England, were not included in the analyses.  
Treatment and Stage 
Information on surgical treatment was obtained from Hospital Episode Statistics data. We used 
codes for 17 major surgical procedures from the Office for Population Censuses and Surveys’ 
Classification of Interventions and Procedures (fourth version) (OPCS-4). (20) These procedures 
include all types of partial and total pancreatectomy (OPCS-4 codes J55.1-2, J55.8-9, J56.1-4, 8 and 
9, and J57.1-5, 8 and 9) (S1 Table), which were designated as of curative intent by pancreatic cancer 
specialists. Patients who received major surgery between one month before and six months after 
diagnosis – regardless of any additional treatment – were assigned to the “resected” group, and 
patients who either received only minor surgery, chemotherapy, radiotherapy or no standard 
oncological treatment were assigned to the “non-resected” group.  
Composite stage at diagnosis was derived from an algorithm that was designed to combine data on 
stage from various sources, prioritising information in the clinical audit data, then data from the 
Cancer Analysis System (CAS) and the National Cancer Registry database. (21) In this study, 
however, the only source of information on stage was the CAS database, because there is currently 
no clinical audit database for pancreatic cancer. Data on the individual tumour (T), nodes (N) and 
metastasis (M) components of stage were combined to derive a summary stage variable with four 
categories, with stage 1 representing localised cancer, stages 2 and 3 representing larger tumours, 
with nearby tissue or lymph nodes involved, and stage 4 indicating metastatic cancer. (22) 
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Statistical Analysis  
Annual incidence rates per 100,000 persons were calculated for each year between 1995 and 2014, 
age-standardised to adjust for changes in the age profile of the population over time. We used the 
European Standard Population weights, modified to reflect only the adult population (15-99 years). 
(23) 
We estimated net survival up to five years after diagnosis. Net survival is the probability of survival 
derived solely from the risk of death from cancer, correcting for the risk of death from other causes 
(background mortality).(24) To enable comparison of survival estimates for all ages combined 
between geographical areas and over time, survival estimates were age-standardised with the 
International Cancer Survival Standard (ICSS) weights. (25) 
Variation in age-standardised net survival between the regions served by each pancreatic centre 
around the pooled estimate for England for patients diagnosed during 2010-2013 is shown in funnel 
plots, (26) in which the survival estimates for each region are plotted on the y-axis against their 
precision (the inverse of the variance) on the x-axis. The control limits, in the shape of a funnel, 
represent the theoretical distribution of survival around the overall mean value for England across 
the observed range of precision of the regional survival estimates, at 95% and 99.8% significance. 
Survival estimates outside the control limits represent regional variation that is wider than would be 
expected from simple random variation, after controlling for differences in the precision of the 
estimates. Linear regression was used to determine the association between the number of resections 
performed in each pancreatic centre during 2010-2013 and one-year net survival for patients who 
were resected. We used the number of patients who were resected, rather than the proportion of 
those referred who were resected, because some HPBs receive a larger number of patients whose 





Pancreatic cancer was diagnosed in 133,325 patients in the 20 years covered by the study (1995-
2014 inclusive). Based on the study eligibility criteria, 132,693 (99.5%) patients were included in 
the incidence analyses, and 121,359 (91.0%) in the national survival analyses (S2 Table). For 81,610 
(61%) patients, the morphology of the pancreatic cancer was registered as ‘not otherwise specified’, 
either because of poor tissue availability or based only on co-axial imaging. These tumours were 
included among the exocrine tumours, since the vast majority of tumours with known morphology 
were exocrine carcinomas.  
For the regional survival analyses (patients diagnosed during 2010-2013), 1,632 (6.2%) of 26,091 
patients were excluded because of missing information on the hospital of treatment, including a 
small proportion of patients who were treated in private hospitals or cared for in hospices or nursing 
homes. In all, 24,459 patients were included in the survival comparisons between the 23 pancreatic 
cancer centre regions (Table 1).  
National Incidence and Survival  
Exocrine pancreatic tumours  
Exocrine carcinomas comprised 97.6% of all pancreatic tumours diagnosed during 1995-2014 (S2 
Table). Age-standardised incidence rates for exocrine tumours rose slightly but steadily from 17.1 
per 105 per year during 1995-1999 to 17.3 during 2000-2004, 18.3 during 2005-2009 and 18.7 during 
2010-2014 (Figure 1). 
Age-standardised one-year net survival for pancreatic exocrine cancers increased from 17.9% for 
patients diagnosed during 2000-2009 to 21.6% in 2010-2013. Five-year net survival increased 
slightly from 3.6% during 2000-2009 to 4.2% in 2010-2013 (S1 Figure). 
Pancreatic neuroendocrine tumours 
Pancreatic neuroendocrine tumours (PNET) comprised only 2.3% of all pancreatic tumours 
diagnosed during 1995-2014 (S2 Table).  Age-standardised incidence rates also rose, but remained 
below 1.0 per 105 per year throughout the 20-year period 1995-2014 (data not shown).   
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For patients diagnosed with a PNET during 2000-2009, one-year net survival was 62.0%, rising to 
71.3% for patients diagnosed during 2010-2013. Five-year net survival for patients diagnosed during 
2000-2009 was 36.5%, rising to 42.9% during 2010-2013 (S1 Figure).  
Variation of Survival by Pancreatic cancer Centre region (exocrine tumours) 
For exocrine tumours, age-standardised one-year net survival varied between centres from 16.1% to 
36.4%, while 5-year survival ranged from 1.7% to 7.6% (Figures 2a & 2b).  
One-year net survival was within the control limits for 19 of the 23 regions (Figure 2a). Survival 
estimates for Manchester and South West London were high outliers, whilst those for Leicester and 
North East London were low outliers. Five-year net survival was also within the control limits for 
19 of the 23 regions (Figure 2b). The estimates for Oxford, South West London, Liverpool and 
Manchester were above the 95% control limit but within the 99.8% limit. The estimates for 
Cambridge, Birmingham, Nottingham and Stoke-on-Trent were low outliers, outside the 99.8% 
limit.  
Variation in Stage, Resection rates and Survival after resection (exocrine tumours) 
For all 24,769 pancreatic exocrine patients diagnosed in 2010-2013, including those treated in 
private hospitals, hospices or nursing homes, stage 1 was reported for 110 (0.4%), stage 2 in 288 
(1.2%), stage 3 in 1,838 (7.4%) and stage 4 in 7,315 (29.5%), but information was missing for 15,218 
patients (61.4%) (Table 2). Among 2,118 resected patients, tumour stage 1 was returned in 18 
(0.9%), stage 2 in 34 (1.6%), stage 3 in 791 (37.3%) and stage 4 in 140 (6.6%), while information 
was missing for 1,135 (53.6%) (Table 2). Among the 398 patients with stage 1 or 2 exocrine cancer, 
52 (13.2%) were resected.  South West England (Plymouth and Bristol) and West Midlands 
(Birmingham, Coventry and Stoke-on-Trent) had the highest proportion of stage 4 tumours (data not 
shown). 
Nationally, only 2,086 (8.9%) of 23,415 patients with an exocrine tumour underwent resection 
(Table 3) in 2010-2013, 13,827 (59.1%) received minor surgery, 977 (4.2%) received only 
chemotherapy and 6,173 (26.4%) underwent only a diagnostic procedure (results not shown). A 
small proportion of patients (1.5%) received other or unrelated procedures.  Among resected 
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patients, net survival was 73.0% at one year and 20.2% at five years (Figure 3a). One- and five-year 
net survival was higher among resected patients than non-resected patients (Figure 3a). 
One-year survival for patients who were resected for an exocrine tumour diagnosed during 2010-
2013 was within the 99.8% control limits for all 23 regions (Figure 3b). Survival in South West 
London and Guildford territories was above the 95% control limit, and in Plymouth, below the 95% 
control limit. Five-year survival ranged between 6.6% and 29.9% for those who were resected and 
between 0.2% and 5.4% for those who were not, but most of these estimates were not statistically 
robust due to the sparseness of data (flagged in S3 Table). The proportion of resections for pancreatic 
exocrine cancers ranged from 5.1% in Nottingham to 19.6% in Oxford (Table 1), but the number of 
resections performed in each centre was not significantly correlated with one-year survival among 
resected patients (r2 = -1.2%).  
DISCUSSION 
The incidence of pancreatic cancer in England has increased slightly over the 20 years between 1995 
and 2014. Similar increases have been reported in the USA and globally, (27-29) suggesting change 
in the prevalence of risk factors.  Whereas smoking has decreased, other risk factors, notably obesity 
and diabetes mellitus, have been increasing. (30) It has been estimated that lifestyle and 
environmental factors accounted for 31.5% of all pancreatic cancers in the UK in 2015. (31)  
Despite small improvements in one-year and five-year survival between 2000 and 2013, pancreatic 
cancer patients continue to experience poor survival. Exocrine carcinomas, which comprise the vast 
majority of pancreatic tumours, have a particularly poor prognosis. Survival for patients who 
underwent resection was much higher than for those who did not. Short-term (one-year) survival 
varied between the regions served by the 23 specialist centres, but the number of resections 
performed at each centre did not explain this variation. At one year after diagnosis, net survival for 
patients diagnosed during 2010-2013 in South West London (36.4%) was much higher than in North 
East London (16.1%). At five years after diagnosis, net survival ranged from 7.6% in Oxford to 
1.7% in Stoke-on-Trent. For most regions, geographic variation around the national average in one-
year and five-year net survival was not wider than would be expected from chance. Only Leicester 
and North East London were low outliers in one-year survival, while Cambridge, Birmingham, 
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Nottingham and Stoke-on-Trent were low outliers in five-year survival. Regional variation in short-
term survival was smaller among patients who were resected.  
Major obstacles in managing exocrine tumours include the lack of specific early symptoms, 
advanced stage at diagnosis, and rapid progression. Emergency presentation is still the most 
common route of diagnosis, and it is linked to lower one-year survival. (32) Patients diagnosed 
following urgent referral by their primary care physician under the “two-week wait” rule may have 
a better prognosis, but only 11% of patients with pancreatic cancer were diagnosed through this 
route, whilst 50% were diagnosed with an emergency presentation in 2006-2008. (33) This has not 
changed much over the last 10 years, such that in 2016, emergency presentation still accounted for 
46% of diagnoses. (32) In some regions, a large proportion of patients are diagnosed with advanced 
disease. In Birmingham and Stoke-on-Trent, 60% of patients were diagnosed with stage 3 or 4 
cancers. These regions were also among the 20 most deprived Local Authority districts in England 
on the Index of Multiple Deprivation 2015. (34) In 2016, emergency presentation was the route of 
diagnosis for 49% of patients living in the most deprived areas, compared with 40% in affluent areas. 
(32) At the same time, Liverpool, Knowsley (part of the Liverpool region) and Manchester Local 
Authorities are amongst the top five with the highest proportions of the most deprived 
neighbourhoods in England, (34) yet Liverpool and Manchester have relatively good survival 
outcomes, so deprivation alone is unlikely to account for the generally poor outcome data.   
This study shows that under-treatment of pancreatic cancer is an important barrier to improving 
outcomes. In the four-year period 2010-2013, only 8.9% of all patients with an exocrine cancer 
received a resection. The National Cancer Registration and Analysis Service reported 23,741 
patients with an exocrine carcinoma between 2013 and 2015, of whom only 1,917 (8.1%) received 
surgery: 1,189 (62.0%) of these patients received both surgery and chemotherapy.(35)  A study of 
147,700 patients diagnosed with pancreatic cancer in the USA, the Netherlands, Belgium, Norway, 
Slovenia, Denmark and Estonia over different periods during 2003-2016, reported that 23,683 
(16.0%) patients underwent a resection. (36) Resection rates varied from 13.1% in Norway and the 
Netherlands to 21.7% in Belgium, whilst adjuvant chemotherapy ranged from 12.0% in Estonia, 
19.2% in Norway, 28.6% in Slovenia, 39.6% in the Netherlands, 55.0% in Belgium, and 55.7% in 
Denmark, whilst 29.5% had chemo-radiotherapy in the USA. (36)  
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In this study from England, resection was only undertaken in 52 (13.2%) of 398 patients known to 
have been diagnosed in stages 1-2 during the four years 2010-2013. The National Cancer 
Registration and Analysis Service reported that 1,252 (39.3%) of 3,186 patients with stage 1-2 
tumours diagnosed during the three years 2013-2015 had a resection, of whom 847 (67.6%) also had 
chemotherapy. (35) These discrepancies are mostly due to a high proportion of missing data on stage 
in the Cancer Analysis System database (more than 60% during 2010-2013) that was used to extract 
the summary stage variable.  
Recording a valid cancer stage at diagnosis is vital for treatment, as well as for actionable research, 
but a major limitation of the NHS data for evaluating outcomes has been the substantial proportion 
of missing information on stage at diagnosis. Data on stage at diagnosis are often missing in the 
clinical record. Since 2012, NHS Digital of Public Heath England has routinely published the 
percentage of all cancer patients for whom a valid stage was recorded, both at national level and by 
Clinical Commissioning Group (CCG), as part of the CCG Outcomes Indicator set. (37) Under this 
system, the validity of stage is assessed according to rules set by the UK and Ireland Association of 
Cancer Registries.  
The completeness of stage data for all cancers diagnosed in England increased from 59.4% in 2012 
to 81.4% in 2017. (37)  A similar increase was seen for pancreatic cancer, from 56% in 2013 to 80% 
in 2017. (35) The improvements can be attributed to more complete pre-operative staging, better 
hospital recording of stage and better registration practice (38), but we have not yet been able to 
access those data. The lack of readily accessible data on stage at diagnosis continues to hamper 
accurate assessment of treatment outcomes at regional and national level. 
In an international study, the proportion of stage 1-2 cancers resected varied from 34% in Norway, 
43% in the USA, and 47% in the Netherlands, to 55.7% in Denmark, 61% in Slovenia, and 63% in 
Belgium. (39) The relatively high proportion of patients receiving adjuvant chemotherapy in 
England compared to Europe and the USA is related to the longstanding leadership taken in England 
with the development of adjuvant chemotherapy through large randomised multicentre clinical trials. 
(5, 40, 41) 
For 2009-2011, the 12-month unadjusted survival for resected stage 1-2 exocrine cancers varied 
from 60% (95% CI: 50–68%) in Slovenia,  68% (65–71%) in  Belgium, 69% (65–72%) in the 
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Netherlands, 70% (68–71%) in the USA, and 77 (70–83%) in Norway. (39) Comparable data for 
survival by treatment and stage in England are not available, either at a national level or by specialist 
centre. (35, 42) 
Other factors that may have contributed to the differences in survival between pancreatic specialist 
centre regions include the quality of medical oncological regimens delivered in the palliative and 
adjuvant settings, the number of specialised surgeons or clinical nurses, and referral patterns 
between local or specialist hospitals, but we have not been able to access these data yet. 
This study showed that one-year and five-year net survival was 21.6% and 4.2%, respectively, for 
patients diagnosed with an exocrine pancreatic cancer in England during the four years 2010-2013. 
Comparable data from the US Surveillance, Epidemiology and End Results (SEER) programme 
show one-year and five year relative survival of 33.5% and 9.3%, respectively, for patients 
diagnosed during 2009-2015. (43) The European Cancer Registry (EUROCARE) programme 
showed that the European average in age-standardised one- and five-year relative survival was 26% 
and 6.9%, respectively, for adults diagnosed with a pancreatic cancer during 1999-2007. (10, 44) 
Centralisation of cancer care in high-volume providers has been a gradual but beneficial process in 
England, as it has led to lower post-operative mortality and morbidity for cancer (45-48) and other 
non-communicable diseases. (49) A study in Finland showed that the proportion of radical surgery 
for pancreatic cancer was higher in healthcare districts with a high level of experience compared to 
regions with a medium or low level of experience, even after adjusting for demographics and 
stage.(50)  
In England, despite the introduction of pancreatic cancer specialist centres more than 10 years ago, 
survival remains lower than in comparably wealthy countries, and this is reflected in low resection 
rates, as well as in the high proportion of patients for whom data on stage and morphology are 
missing. Taken together, these observations reflect an inability to provide timely access to full 
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LEGENDS to FIGURES 
Figure 1. Trends in the age-standardised annual incidence rate for pancreatic exocrine tumours in 
England, 1995-2014. 
Figure 2. Funnel plot of age-standardised net survival at (a)  one year and (b)  five years, in the 23 
pancreatic cancer centre regions*, for patients diagnosed with a pancreatic exocrine tumour in 
England during 2010-2013. 
Figure 3. (a) Age-standardised one- and five-year net survival (%) for exocrine pancreatic cancer 
by resection status in England during 2010-2013. (b) Funnel plot of age-standardised one-year net 
survival for resected patients with a pancreatic exocrine tumour in the 23 pancreatic cancer centre 
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Table 1. Proportion of resected and non-resected pancreatic tumours in the 23 pancreas regions in England, 2010-2013 inclusive. 
 
  Pancreatic Exocrine carcinomas   Pancreatic neuro-endocrine tumours   All Tumours* 
HPB territory 
Resected  Not resected  Total  Resected  Not resected  Total   
No. %  No. %    No. %  No. %     
London South 
East 
149 10.7  1,249 89.3  1,398  20 37.7  33 62.3  53  1,452 
London South 
West 
58 10.5  492 89.5  550  9 28.1  23 71.9  32  584 
London North 
East 
66 6.7  912 93.3  978  18 42.9  24 57.1  42  1,020 
London North 
West 
76 14.0  465 86.0  541  10 30.3  23 69.7  33  574 
London North 117 8.1  1,330 91.9  1,447  30 40.0  45 60.0  75  1,525 
Cambridge 139 8.2  1,559 91.8  1,698  32 38.1  52 61.9  84  1,784 
Leicester 50 7.1  651 92.9  701  10 47.6  11 52.4  21  722 
Nottingham 54 5.1  1,008 94.9  1,062  9 28.1  23 71.9  32  1,095 
Guildford 73 7.3  923 92.7  996  6 23.1  20 76.9  26  1,022 
Oxford 132 19.6  542 80.4  674  15 50.0  15 50.0  30  704 
Southampton 123 7.8  1,454 92.2  1,577  15 30.6  34 69.4  49  1,628 
Plymouth 110 10.1  982 89.9  1,092  7 25.9  20 74.1  27  1,119 
Bristol 64 8.9  653 91.1  717  10 26.3  28 73.7  38  755 
Birmingham 132 7.4  1,658 92.6  1,790  25 25.5  73 74.5  98  1,888 
Coventry 45 12.0  329 88.0  374  8 47.1  9 52.9  17  392 
Stoke-on-Trent 51 8.8  531 91.2  582  13 52.0  12 48.0  25  607 
Hull 51 8.4  553 91.6  604  9 32.1  19 67.9  28  633 
Leeds 94 6.5  1,363 93.5  1,457  23 29.1  56 70.9  79  1,538 
Sheffield 79 9.1  789 90.9  868  14 48.3  15 51.7  29  897 
Newcastle 96 7.6  1,165 92.4  1,261  27 42.2  37 57.8  64  1,325 
Blackburn 61 7.1  800 92.9  861  6 21.4  22 78.6  28  890 
Liverpool 121 11.4  940 88.6  1,061  22 40.0  33 60.0  55  1,117 
Manchester 145 12.9  981 87.1  1,126  28 45.9  33 54.1  61  1,188 
All centres 2,086 8.9  21,329 91.1  23,415  366 35.7  660 64.3  1,026  24,459 
Private hospitals 4 1.6  242 98.4  246  1 25.0  3 75.0  4  251 
Other 28 2.5  1080 97.5  1,108  4 14.8  23 85.2  27  1,136 
Total 2,118 8.6  22,651 91.4  24,769  371 35.1  686 64.9  1,057  25,846 
*Total number of patients, including patients diagnosed with pancreatic tumours of rare morphologies.  
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Table 2. Proportion of pancreatic exocrine tumours patients by stage and treatment: England, 2010-2013. Total = 24,679. 
 
  No Resection   Resection  Total 
Age group Stage No. %   No. %  No. % 
           
15-44 Stage 1                -    0.0                  -    0.0                 -    0 
 Stage 2                 2  40.0                   3  60.0                  5  100 
 Stage 3               12  44.4                 15  55.6                27  100 
 Stage 4             115  95.8                   5  4.2              120  100 
 Missing             178  80.5                 43  19.5              221  100 
 
          
45-54 Stage 1                 3  37.5                   5  62.5                  8  100 
 Stage 2               16  84.2                   3  15.8                19  100 
 Stage 3               73  44.8                 90  55.2              163  100 
 Stage 4             502  98.0                 10  2.0              512  100 
 Missing             718  85.5               122  14.5              840  100 
 
          
55-64 Stage 1               10  76.9                   3  23.1                13  100 
 Stage 2               28  77.8                   8  22.2                36  100 
 Stage 3             186  48.6               197  51.4              383  100 
 Stage 4          1,406  97.0                 43  3.0           1,449  100 
 Missing          2,158  87.4               312  12.6           2,470  100 
 
          
65-74 Stage 1               20  71.4                   8  28.6                28  100 
 Stage 2               54  78.3                 15  21.7                69  100 
 Stage 3             342  49.9               344  50.1              686  100 
 Stage 4          2,324  97.7                 54  2.3           2,378  100 
 Missing          3,832  90.0               426  10.0           4,258  100 
 
          
75-99 Stage 1               59  96.7                   2  3.3                61  100 
 Stage 2             154  96.9                   5  3.1              159  100 
 Stage 3             434  75.0               145  25.0              579  100 
 Stage 4          2,828  99.0                 28  1.0           2,856  100 
 Missing          7,197  96.9               232  3.1           7,429  100 
 
          
All ages Stage 1               92  83.6                 18  16.4              110  100 
 Stage 2             254  88.2                 34  11.8              288  100 
 Stage 3          1,047  57.0               791  43.0           1,838  100 
 Stage 4          7,175  98.1               140  1.9           7,315  100 
    Missing        14,083  92.5             1,135  7.5          15,218  100 
 
 








Figure 2. Funnel plot of age-standardised net survival at (a) one year and (b) five years, in the 23 pancreatic 
cancer centre regions*, for patients diagnosed with a pancreatic exocrine tumour in England during 2010-
2013 











*1 - London South East, 2 - London South West, 3 - London North East, 4 - London North West, 5 - London 
North, 6 - Cambridge, 7 - Leicester, 8 - Nottingham, 9 - Guildford, 10 - Oxford, 11 - Southampton, 12 - Plymouth, 
13 - Bristol, 14 - Birmingham, 15 - Coventry, 16 - Stoke-on-Trent, 17- Hull, 18 - Leeds, 19 - Sheffield, 20 - 





































Figure 3. (a)Age-standardised one- and five-year net survival (%) for exocrine pancreatic cancer by 
resection status in England during 2010-2013 (b) Funnel plot of age-standardised one-year net survival for 







* 1 - London South East, 2 - London South West, 3 - London North East, 4 - London North West, 5 - London 
North, 6 - Cambridge, 7 - Leicester, 8 - Nottingham, 9 - Guildford, 10 - Oxford, 11 - Southampton, 12 - Plymouth, 
13 - Bristol, 14 - Birmingham, 15 - Coventry, 16 - Stoke-on-Trent, 17 - Hull, 18 - Leeds, 19 - Sheffield, 20 - 
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S1 Table. Classification of Interventions and Procedures Version 4 (OPCS-4) codes of major resections for 
pancreatic cancer 
OPCS-4 Codes for major resections for Pancreatic Cancer 
J55.1 Total pancreatectomy and excision of surrounding tissue 
J55.2 Total pancreatectomy not elsewhere classified 
J55.8 Other specified total excision of pancreas 
J55.9 Unspecified specified excision of pancreas 
J56.1 Pancreaticoduodenectomy and excision of surrounding tissue 
J56.2 Pancreaticoduodenectomy and resection of antrum of stomach 
J56.3 Pancreaticoduodenectomy not elsewhere classified 
J56.4 Subtotal excision of head of pancreas with preservation of duodenum and 
drainage HFQ J56.8 Other specified excision of head of pancreas 
J56.9 Unspecified excision of head of pancreas 
J57.1 Subtotal pancreatectomy 
J57.2 Left pancreatectomy and drainage of pancreatic duct 
J57.3 Left pancreatectomy not elsewhere classified  
J57.4 Excision of tail of pancreas and drainage of pancreatic duct 
J57.5 Excision of tail of pancreas not elsewhere classified 
J57.8 Other specified partial excision of pancreas 





S2 Table. Number of patients diagnosed with Pancreatic Exocrine Carcinomas, Pancreatic 
Neuroendocrine Tumours (PNET) and Other malignant tumours: England, 1995-2014. 
Morphology code 
 Number of cases 
(1995-2014)  % 
Pancreatic Exocrine Carcinomas 
8000 Neoplasm, malignant 
                             
22,003  16.6 
8001 Tumour cells, malignant 
                                       
45  0.0 
8002 Malignant tumour, small cell type 
                                          
1  0.0 
8003 Malignant tumour, giant cell type 
                                       
10  0.0 
8004 Malignant tumour, fusiform cell type 
                                          
4  0.0 
8010 Carcinoma NOS 
                             
59,607  44.9 
8011 Epithelioma, malignant 
                                          
2  0.0 
8012 Large cell carcinoma NOS 
                                       
65  0.0 
8020 Carcinoma, undifferentiated NOS 
                                    
104  0.1 
8021 Carcinoma, anaplastic NOS 
                                    
101  0.1 
8022 Pleomorphic carcinoma 
                                       
24  0.0 
8031 Giant cell carcinoma 
                                       
13  0.0 
8032 Spindle cell carcinoma 
                                       
18  0.0 
8033 Pseudosarcomatous carcinoma 
                                          
6  0.0 
8040 Tumorlet, NOS 
                                          
3  0.0 
8046 Non-small cell carcinoma 
                                          
3  0.0 
8050 Papillary carcinoma NOS 
                                       
29  0.0 
8070 Squamous cell carcinoma NOS 
                                    
150  0.1 
8071 Squamous cell carcinoma, keratinizing NOS 
                                       
15  0.0 
8072 
Squamous cell carcinoma, large cell, 
nonkeratinizing 
                                          
3  0.0 
8140 Adenocarcinoma NOS 
                             
41,916  31.6 
8141 Scirrhous adenocarcinoma 
                                       
30  0.0 
8143 Superficial spreading adenocarcinoma 
                                          
2  0.0 
8144 Adenocarcinoma, intestinal type   
                                       
13  0.0 
8145 Carcinoma, diffuse type   
                                          
9  0.0 
8160 Cholangiocarcinoma   
                                       
16  0.0 
8200 Adenoid cystic carcinoma 
                                          
5  0.0 
8201 Cribriform carcinoma 
                                          
1  0.0 
8210 Adenocarcinoma in adenomatous polyp 
                                          
2  0.0 
8211 Tubular adenocarcinoma 
                                       
26  0.0 
8230 Solid carcinoma NOS 
                                          
1  0.0 
8245 Adenocarcinoid tumour 
                                          
2  0.0 
8251 Alveolar adenocarcinoma   
                                          
1  0.0 
8260 Papillary adenocarcinoma NOS 
                                    
126  0.1 
8261 Adenocarcinoma in villous adenoma 
                                          
5  0.0 
8262 Villous adenocarcinoma 
                                          
1  0.0 
8263 Adenocarcinoma in tubulovillous adenoma 
                                          
7  0.0 
8290 Oxyphilic adenocarcinoma 
                                          
7  0.0 
8310 Clear cell adenocarcinoma NOS 
                                       
46  0.0 
8323 Mixed cell adenocarcinoma 
                                          
1  0.0 
8401 Apocrine adenoma 
                                          
1  0.0 
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8430 Mucoepidermoid carcinoma 
                                          
2  0.0 
8440 Cystadenocarcinoma NOS 
                                    
140  0.1 
8441 Serous cystadenocarcinoma NOS   
                                          
1  0.0 
8450 Papillary cystadenocarcinoma NOS   
                                          
5  0.0 
8452 Solid pseudopapillary carcinoma 
                                       
31  0.0 
8470 Mucinous cystadenocarcinoma NOS   
                                       
62  0.0 
8471 Papillary mucinous cystadenocarcinoma   
                                       
47  0.0 
8480 Mucinous adenocarcinoma 
                                    
984  0.7 
8481 Mucin-producing adenocarcinoma 
                                    
919  0.7 
8490 Signet ring cell carcinoma 
                                    
146  0.1 
8500 Infiltrating duct carcinoma   
                                
2,226  1.7 
8503 
Intraductal papillary adenocarcinoma with 
invasion   
                                       
11  0.0 
8510 Medullary carcinoma NOS 
                                          
1  0.0 
8521 Infiltrating ductular carcinoma   
                                          
1  0.0 
8550 Acinar cell carcinoma 
                                    
161  0.1 
8560 Adenosquamous carcinoma 
                                    
304  0.2 
8570 Adenocarcinoma with squamous metaplasia 
                                          
6  0.0 
Total Exocrine 
                         
129,471  97.6 
Pancreatic Neuroendocrine Tumours (PNET) 
8041 Small cell carcinoma NOS 
                                    
127  0.1 
8150 Islet cell carcinoma   
                                    
154  0.1 
8151 Insulinoma, malignant   
                                       
90  0.1 
8152 Glucagonoma, malignant   
                                       
15  0.0 
8153 Gastrinoma, malignant 
                                       
41  0.0 
8154 Mixed islet cell and exocrine adenocarcinoma   
                                       
19  0.0 
8155 Vipoma 
                                          
7  0.0 
8240 Carcinoid tumour NOS   
                                    
764  0.6 
8241 Enterochromaffin cell carcinoid 
                                          
2  0.0 
8243 Goblet cell carcinoid   
                                          
1  0.0 
8244 Composite carcinoid 
                                          
5  0.0 
8246 Neuroendocrine carcinoma 
                                
1,888  1.4 
8248 Apudoma 
                                          
1  0.0 
8360 Multiple endocrine adenomas 
                                          
1  0.0 
Total PNET 
                               
3,115  2.3 
Other  
8720 Malignant melanoma NOS 
                                          
1  0.0 
8800 Sarcoma NOS 
                                       
26  0.0 
8801 Spindle cell sarcoma 
                                          
4  0.0 
8802 Giant cell sarcoma   
                                          
3  0.0 
8803 Small cell sarcoma 
                                          
2  0.0 
8810 Fibrosarcoma NOS 
                                          
1  0.0 
8830 Fibrous histiocytoma, malignant 
                                          
1  0.0 
8850 Liposarcoma NOS 
                                          
2  0.0 
8858 Dedifferentiated liposarcoma 
                                          
1  0.0 
8890 Leiomyosarcoma NOS 
                                       
24  0.0 
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8891 Epithelioid leiomyosarcoma 
                                          
1  0.0 
8900 Rhabdomyosarcoma NOS 
                                          
1  0.0 
8920 Alveolar rhabdomyosarcoma 
                                          
1  0.0 
8933 Adenosarcoma 
                                          
7  0.0 
8940 Mixed tumour, malignant NOS 
                                          
3  0.0 
8971 Pancreatoblastoma   
                                          
6  0.0 
8980 Carcinosarcoma NOS 
                                          
8  0.0 
8990 Mesenchymoma, malignant 
                                          
4  0.0 
9070 Embryonal carcinoma NOS 
                                          
1  0.0 
9080 Teratoma, malignant NOS 
                                          
1  0.0 
9120 Haemangiosarcoma 
                                          
1  0.0 
9130 Haemangioendothelioma, malignant 
                                          
1  0.0 
9363 Melanotic neuroectodermal tumor 
                                          
2  0.0 
9364 Peripheral neuroectodermal tumour 
                                          
5  0.0 
Total Other 
                                   
107  0.1 
All pancreatic tumours 
                          
132,693  100.0 
 
*NOS= not otherwise specified 
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S3 Table. Age-standardised net survival (%) at one and five years after diagnosis from pancreatic 
exocrine tumours in the 23 pancreas regions in England, 2010-2013 inclusive. 










survival  95% CI 
 
Net 
survival 95% CI 
 
Net 
survival 95% CI 
 
Net 
survival 95% CI 
London South 
East 
13.4 13.1 13.6  72.1 67.0 77.3  2.8 2.8 2.8  21.9 20.5 23.3 
London South 
West 
31.0 29.7 32.3  82.7 74.8 90.6  5.4¬ 5.2 5.5  22.6¬ 20.2 25.0 
London North 
East 
12.5 12.2 12.8  68.6 60.4 76.8  1.8 1.8 1.9  29.9¬ 26.2 33.7 
London North 
West 
19.5 18.7 20.3  76.1¬ 68.5 83.8  4.5¬ 4.4 4.6  20.2¬ 18.2 22.3 
London North 16.1 15.7 16.4  71.2 65.5 77.0  2.6 2.5 2.6  19.4 18.0 20.9 
Cambridge 14.6 14.3 14.9  76.1 70.8 81.3  0.2¬ 0.2 0.2  19.0 17.8 20.2 
Leicester 11.2 10.9 11.5  74.1 65.2 83.0  1.2¬ 1.2 1.2  16.2¬ 14.7 17.7 
Nottingham 14.6 14.2 14.9  72.2 63.5 80.8  1.7 1.7 1.7  16.1¬ 14.5 17.7 
Guildford 15.7 15.2 16.1  83.3 76.4 90.2  1.2¬ 1.1 1.2  20.1 18.2 22.0 
Oxford 13.5 13.1 14.0  68.6 63.2 74.0  1.9¬ 1.8 1.9  24.1 22.2 26.1 
Southampton 14.5 14.2 14.8  78.2 72.7 83.7  1.3¬ 1.2 1.3  19.8 18.4 21.2 
Plymouth 14.9 14.5 15.3  62.3 56.9 67.8  3.4¬ 3.4 3.5  16.7¬ 15.5 17.9 
Bristol 16.3 15.7 16.8  76.8 68.7 84.9  2.1¬ 2.1 2.1  12.6¬ 11.5 13.6 
Birmingham 14.7 14.4 15.0  70.5 65.1 75.9  1.4 1.4 1.4  15.7 14.8 16.6 
Coventry 13.1 12.6 13.6  66.8¬ 57.9 75.7  1.4* 0.0 2.8  21.5¬ 19.1 23.9 
Stoke-On-Trent 13.0 12.6 13.5  78.8 69.5 88.1  0.7¬ 0.7 0.7  6.6¬ 6.2 7.1 
Hull 15.4 14.9 15.9  64.8¬ 56.5 73.2  1.0¬ 1.0 1.0  21.4¬ 19.1 23.7 
Leeds 16.0 15.7 16.3  69.0 63.0 75.1  1.3¬ 1.3 1.3  23.8 22.0 25.6 
Sheffield 13.6 13.2 14.0  67.4 60.6 74.2  1.3¬ 1.3 1.3  14.2¬ 13.2 15.2 
Newcastle 12.5 12.3 12.8  79.7 73.6 85.8  0.8¬ 0.8 0.8  22.1¬ 20.3 23.9 
Blackburn 11.6 11.4 11.9  79.7 72.1 87.4  1.9¬ 1.9 1.9  25.4¬ 22.5 28.2 
Liverpool 15.0 14.6 15.4  66.1 60.9 71.4  4.2¬ 4.1 4.2  19.6 18.2 21.0 
Manchester 18.8 18.2 19.3   71.7 66.9 76.6   2.6 2.6 2.7   22.7 21.2 24.3 
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S1 Figure. Age-standardised one- and five-year net survival* (%) for pancreatic cancer by morphology 
group and calendar period of diagnosis in England, 2000-2013 inclusive. 
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